XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (629,128) $ (210,480)
Adjustments to reconcile net loss to net cash used in operating activities:    
Goodwill Impairment 436,479  
Depreciation and amortization expense 23,216 19,543
Provisions for credit losses 88 63
Amortization of deferred contract acquisition costs 1,611 1,295
Amortization of deferred contract fulfillment costs 323 452
Noncash compensation costs incurred by selling shareholders   5,923
Stock-based compensation expense 59,567 48,419
Loss on equity method investment 1,877 1,355
Deferred income taxes (24) (1,390)
Changes in operating assets and liabilities, net of acquisition:    
Accounts receivable 11,475 4,796
Inventories 905 (439)
Deferred contract acquisition costs (2,351) (2,035)
Prepaid expenses and other current assets 4,976 (924)
Other assets (214) (276)
Accounts payable (2,357) (5,797)
Accrued expenses and other current liabilities (16,579) 1,166
Other long-term liabilities   (25)
Deferred revenue 3,369 (18,023)
Net cash used in operating activities (106,767) (156,377)
Cash flows from investing activities:    
Purchases of property and equipment (96) (2)
Capitalized software development costs (13,836)  
Investment in less than majority owned joint venture (3,920) (1,960)
Purchases of investments (389,990) (499,223)
Proceeds from sales and maturities of investments 294,335 249,855
Net cash used in investing activities (113,507) (251,330)
Cash flows from financing activities:    
Proceeds from exercise of common stock options 569 5,323
Proceeds from employee stock purchase plan 2,164 2,503
Payments for the purchase of treasury stock (586) (360)
Proceeds from Section 16(b) disgorgement   295
Payment of contingent consideration   (11,790)
Net cash provided by (used in) financing activities 2,147 (4,029)
Effect of exchange rates changes on cash, cash equivalents, and restricted cash (1,046) (2,079)
Net decrease in cash, cash equivalents, and restricted cash (219,173) (413,815)
Cash, cash equivalents, and restricted cash at beginning of period 539,341 747,211
Cash, cash equivalents, and restricted cash at end of period 320,168 333,396
Cash, cash equivalents, and restricted cash at end of period:    
Cash and cash equivalents 319,373 332,601
Restricted cash 795 795
Total cash, cash equivalents, and restricted cash at end of period 320,168 333,396
Supplemental disclosure of cash flow information:    
Cash paid (refunded) for income taxes $ 4,067 1,167
Supplemental disclosure of non-cash investing and financing activities:    
Issuance of common stock in settlement of earnout   $ 17,243